THE GLIVEC INTERNATIONAL SITE

References

1. Glivec Summary of Product Characteristics [SMPC]. Basel, Switzerland: Novartis Pharma AG; 2005.

2. Druker BJ, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukaemia. The New England Journal of Medicine.(2007 April).

Disclaimer: This is an international website for Glivec^® (imatinib) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.

Home | About Glivec | CML | GIST | For Your Patients | News & Events | Resources
Safety and Tolerability | European Summary of Product Characteristics

About Novartis Oncology | Contact | Site Map | Help | Privacy

Use of this website is subject to our Terms of Use.
© 2010 Novartis AG